
After a GLP-1: what exit strategy allows you to maintain weight?
NATIONAL HARBOR, Md. — Among more than 20,000 patients who took semaglutide or tirzepatide, those who pursued bariatric surgery, although the least likely choice, had the most weight loss after 2 years, while those who stopped treatment completely had the least, new data show.
“To our knowledge, this is the first study comparing weight change and cardiometabolic parameters across multiple obesity treatment strategies in patients who initially took semaglutide or tirzepatide injection for obesity or type 2 diabetes,” said Hamlet Gasoyan, DS, PhD, MPH, assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Ohio. Medscape Medical News.
“Our findings could support patient-clinician discussions about alternative treatment options in patients who are considering changing or stopping these medications,” Gasoyan said of the study, presented at Obesity Week and published simultaneously in eMedicineClinical.
Although GLP-1 semaglutide and GLP-1/GIP tirzepatide have led the way in revolutionizing the obesity treatment landscape in recent years, one-year drug discontinuation rates range from 47% to 65%, Gasoyan and colleagues note.
Without switching to another method of treating obesity, studies show that stopping the medications results in a reversal of any weight lost on the medications – and their cardiometabolic benefits.
Lacking research comparing outcomes with the variety of alternatives to discontinuation, Gasoyan and colleagues conducted a target emulation trial using electronic health record data from 20,486 patients at Cleveland Clinic centers in Ohio and Florida who were initially treated for obesity or type 2 diabetes with semaglutide (n = 15,154; 74%) or tirzepatide (n = 5,332). 26%) between January 2021 and December 2023 and thereafter. until December 2025.
All patients had been treated according to their initial treatment, the reference period, for at least 3 months. Their average body weight at the start of the trial was 109 kg (240 lb), which represented a reduction of 2.3 kg (2.1%) from the start of initial treatment, and 51% of patients reached the highest dose during their run-in period.
Overall, 65.7% of patients had type 2 diabetes and 68% had hypertension. They had a mean age of 56.7 years, 63% were women and their mean BMI was 38 kg/m.2.
The results of the per-protocol analysis showed that after 2 years, the initial weight loss observed during the baseline period was either maintained or increased with most strategies: for those who continued to take their original medication, the weight loss was 10.9%.
For those who switched from semaglutide to tirzepatide (either way), the reduction was 16%; for those who switched to another obesity medication, the reduction was 8.2%; for metabolic bariatric surgery the reduction was 28.2% and for those who stopped treatment the reduction was 4%.
Patients initially on semaglutide who switched to tirzepatide experienced greater weight loss compared to continued semaglutide (difference of 3.0 kg (6.6 lb)), while for patients who continued to take tirzepatide, greater weight loss was observed compared to switching to semaglutide (difference of 4.5 kg (10 lb)).
Additionally, similar trends were observed in changes in HbA1c and systolic blood pressure.
While bariatric surgery was associated with the most substantial weight reduction, Gasoyan noted that a very small percentage made this choice.
“About 1% of patients who stop semaglutide or tirzepatide undergo bariatric surgery within a year of stopping,” he said.
In terms of safety outcomes, there was no significant difference between patients initiated on tirzepatide and those initiated on semaglutide in the risk of all-cause emergency department visits or a composite outcome of biliary disease, pancreatitis, bowel obstruction, or gastroparesis requiring an emergency department visit or hospitalization during the initial drug titration phase. However, the study did not compare adverse events between treatment strategies.
Of note, patients who had an emergency room visit or composite outcome during their first 90 days of treatment were 1.8 times more likely to discontinue their reference medication than those who did not.
The authors acknowledge that the study was observational and estimated a hypothetical effect of adherence to each strategy. They note that unmeasured confounders, compounded medications, cost and insurance barriers, and limited generalizability may have influenced the results, and that prospective real-world studies are needed to confirm the findings.
The study authors point out that the results fill an important gap in the need for research on the outcomes of option switching.
“The lack of comparative data on the effectiveness of alternative options after discontinuation of new obesity medications has been highlighted in the literature,” they write.
“This issue is of great importance because obesity is a chronic disease that requires lifelong treatment.”
Ultimately, the results “highlight the importance of continued obesity management and show that for patients who need to stop their GLP-1 injectable therapy, this does not mean their obesity treatment journey has to end,” Gasoyan said.
Gasoyan noted that, moving forward, his team plans to use its data to develop evidence-based decision support to help patients choose treatment after stopping their obesity medication.
“We hope that decision support will help patients choose a treatment informed by their expected benefits and risks and aligned with their preferences,” he said.
“Realistic expectations”
Commenting on the study, session moderator Maria Daniela Hurtado Andrade, MD, PhD, assistant professor at the Mayo Clinic Alix School of Medicine, Jacksonville, Florida, echoed this “The patient journey is important when we talk and discuss treatment options.
“We know that previous treatment strategies that have been used for obesity can affect patient outcomes, and learning from this research will help us give our patients more personalized advice about what to expect,” she said. Medscape Medical News.
Caveats include the need to further evaluate whether specific characteristics predispose patients to certain outcomes, such as higher BMI at baseline or the presence of comorbidities, she noted.
However, the results offer important insights into the outcomes of treatment choices, “which are not necessarily what we see in clinical trials,” Andrade noted.
“So, for me, that’s kind of the essence of the study: being able to give patients more personalized advice and discuss more realistic expectations.”
Gasoyan has not reported any relevant financial relationships. Andrade previously served on an advisory board for Novo Nordisk, Viking Therapeutics, Roche and Boehringer Ingelheim.
Gn Health